Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1987 Nov;70(2):328–335.

Dose-response effects in immunizations with keyhole limpet haemocyanin and rabies vaccine: shift in some immunodeficiency states.

K Korver 1, E W Boeschoten 1, R T Krediet 1, G van Steenis 1, P T Schellekens 1
PMCID: PMC1542077  PMID: 3427825

Abstract

We investigated the primary antibody response to the antigens keyhole limpet haemocyanin (KLH) and rabies vaccine (RV). Eighty-one healthy volunteers were injected with nine doses of KLH (ranging from 10 to 2500 micrograms) and 66 volunteers with six doses of RV (ranging from 17 to 680 micrograms protein). Anti-KLH and anti-RV antibodies were determined by ELISA and immunofluorescence (IF) immediately before and 14 days after primary immunization. On the basis of the dose-response curves, optimal and supra-optimal antigen doses were chosen for the assessment of humoral immunocompetence in two groups of patients with uraemic disease, who were treated either by chronic intermittent (hospital) haemodialysis (HD) (n = 16), or continuous ambulatory peritoneal dialysis (CAPD) (n = 23). The patients were randomly immunized with 250 micrograms or 2.5 mg KLH and 170 micrograms or 680 micrograms RV and their antibody responses were compared with those obtained in healthy individuals. We found a definite deficiency in the primary response in haemodialysis patients after challenging with a suitable antigen dose. However, the differences in response rate between patients and controls tended to disappear upon stimulation with a supra-optimal antigen dose. This might indicate that the dose-response curve of a particular antigen is shifted towards higher doses of antigen in immunodeficiency states, which could have important consequences for the testing of immunocompromised patients.

Full text

PDF
328

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adorini L., Doria G. Defective antigen presentation by macrophages from mice genetically selected for low antibody response. Eur J Immunol. 1981 Dec;11(12):984–989. doi: 10.1002/eji.1830111207. [DOI] [PubMed] [Google Scholar]
  2. Alevy Y. G., Mueller K. R., Slavin R. G. Immune response in experimentally induced uremia. VI. Uremic macrophages are defective in their ability to present antigen to T cells. Clin Immunol Immunopathol. 1983 Dec;29(3):433–442. doi: 10.1016/0090-1229(83)90046-6. [DOI] [PubMed] [Google Scholar]
  3. Barkin R. M., Samuelson J. S., Gotlin L. P. DTP reactions and serologic response with a reduced dose schedule. J Pediatr. 1984 Aug;105(2):189–194. doi: 10.1016/s0022-3476(84)80111-0. [DOI] [PubMed] [Google Scholar]
  4. Benhamou E., Courouce A. M., Jungers P., Laplanche A., Degos F., Brangier J., Crosnier J. Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol. 1984 Mar;21(3):143–147. [PubMed] [Google Scholar]
  5. Biozzi G. Correlation between genetic regulation of immune responsiveness and host defence against infections and tumours. Eur J Clin Invest. 1982 Oct;12(5):373–376. doi: 10.1111/j.1365-2362.1982.tb00681.x. [DOI] [PubMed] [Google Scholar]
  6. Cano F. R., Querry M. V., Tarrant C. J., Ritchey M. B., Schiffman G. Antibody responses after immunization with polyvalent pneumococcal vaccine containing 10, 25, or 50 micrograms of 14 polysaccharide types per dose. Proc Soc Exp Biol Med. 1983 Sep;173(4):579–582. doi: 10.3181/00379727-173-41690. [DOI] [PubMed] [Google Scholar]
  7. Friedmann P. S., Moss C., Shuster S., Simpson J. M. Quantitative relationships between sensitizing dose of DNCB and reactivity in normal subjects. Clin Exp Immunol. 1983 Sep;53(3):709–715. [PMC free article] [PubMed] [Google Scholar]
  8. Goldblum S. E., Reed W. P. Host defenses and immunologic alterations associated with chronic hemodialysis. Ann Intern Med. 1980 Oct;93(4):597–613. doi: 10.7326/0003-4819-93-4-597. [DOI] [PubMed] [Google Scholar]
  9. Korver K., Zeijlemaker W. P., Schellekens P. T., Vossen J. M. Measurement of primary in vivo IgM- and IgG-antibody response to KLH in humans: implications of pre-immune IgM binding in antigen-specific ELISA. J Immunol Methods. 1984 Nov 30;74(2):241–251. doi: 10.1016/0022-1759(84)90291-6. [DOI] [PubMed] [Google Scholar]
  10. Lelie P. N., Reesink H. W., de Jong-van Manen S. T., Dees P. J., Reerink-Brongers E. E. Immune response to a heat-inactivated hepatitis B vaccine in patients undergoing hemodialysis. Enhancement of the response by increasing the dose of hepatitis B surface antigen from 3 to 27 micrograms. Arch Intern Med. 1985 Feb;145(2):305–309. [PubMed] [Google Scholar]
  11. Oreopoulos D. G., Khanna R., Williams P., Vas S. I. Continuous ambulatory peritoneal dialysis - 1981. Nephron. 1982;30(4):293–303. doi: 10.1159/000182504. [DOI] [PubMed] [Google Scholar]
  12. Primary immunodeficiency diseases. Report of a World Health Organization scientific group. Clin Immunol Immunopathol. 1986 Jul;40(1):166–196. [PubMed] [Google Scholar]
  13. Siber G. R., Ransil B. J., Schiffman G. Graphical method for evaluating antibody response to vaccines. Infect Immun. 1980 May;28(2):641–644. doi: 10.1128/iai.28.2.641-644.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Smith J. S., Yager P. A., Baer G. M. A rapid reproducible test for determining rabies neutralizing antibody. Bull World Health Organ. 1973 May;48(5):535–541. [PMC free article] [PubMed] [Google Scholar]
  15. Szmuness W., Stevens C. E., Harley E. J., Zang E. A., Taylor P. E., Alter H. J. The immune response of healthy adults to a reduced dose of hepatitis B vaccine. J Med Virol. 1981;8(2):123–129. doi: 10.1002/jmv.1890080206. [DOI] [PubMed] [Google Scholar]
  16. de Graeff P. A., Dankert J., de Zeeuw D., Gips C. H., van der Hem G. K. Immune response to two different hepatitis B vaccines in haemodialysis patients: a 2-year follow-up. Nephron. 1985;40(2):155–160. doi: 10.1159/000183453. [DOI] [PubMed] [Google Scholar]
  17. van Tol M. J., Zijlstra J., Thomas C. M., Zegers B. J., Ballieux R. E. Distinct role of neonatal and adult monocytes in the regulation of the in vitro antigen-induced plaque-forming cell response in man. J Immunol. 1984 Oct;133(4):1902–1908. [PubMed] [Google Scholar]
  18. van Wezel A. L., van Steenis G., Hannik C. A., Cohen H. New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Dev Biol Stand. 1978;41:159–168. [PubMed] [Google Scholar]
  19. van Wezel A. L., van Steenis G. Production of an inactivated rabies vaccine in primary dog kidney cells. Dev Biol Stand. 1978;40:69–75. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES